Arrowhead Pharmaceuticals receives Orphan Drug designation for ARO-ANG3
Arrowhead Pharmaceuticals announced the FDA has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH). The company began dosing ARO-ANG3 in a first-in-human study (AROANG1001) in January 2019. July 16, 2019